Bennett, J. M., Catovsky, D., Daniel, M. T.et al. (1976). Proposals for the classification of the acute leukaemias. Br. J. Haematol., 33, 451–8CrossRefGoogle ScholarPubMed

Bennett, J. M., Catovsky, D., Daniel, M. T.et al. (1982). Proposals for the classification of the myelodysplastic syndromes. Br. J. Haematol., 51, 189–99CrossRefGoogle ScholarPubMed

Brunning, R. D., Bennett, J. M., Flandrin, G. et al. (2001). Myelodysplastic syndromes and acute myeloid leukaemias. In World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, ed. , E. S. Jaffe, , N. L. Harris, , H. Stein and , J. W. Vardiman. Lyon: IARC Press, pp. 61–106Google Scholar

Brunning, R. D. and McKenna, R. W. (1994). Myelodysplastic syndromes. In Tumors of the Bone Marrow, Atlas of Tumor Pathology, third series, fascicle 9, ed. , J. Rosai. Washington, DC: Armed Forces Institute of Pathology, pp. 143–94Google Scholar

Phelan, J. T. II, Kouides, P. A., and Bennett, J. M. (2002). Myelodysplastic syndromes: historical aspects and classification. New York: Marcel Dekker, pp. 1–14Google Scholar

Balduini, C. L., Guarnone, R., Pecci, A., Centenara, E., and Ascari, E. (1998). Multilineage dysplasia without increased blasts identifies a poor prognosis subset of myelodysplastic syndromes. Leukemia, 12, 1655–6 (letter)CrossRefGoogle ScholarPubMed

Michels, S., Chan, W., Jakubowski, D., and Vogler, R. (1990). Unclassifiable myelodysplastic syndrome: a study of sixteen cases with a proposal for a new subtype. Lab. Invest., 62, 67 (abstract)Google Scholar

Rosati, S., Mick, R., Xu, F.et al. (1996). Refractory cytopenia with multilineage dysplasia: further characterization of an “unclassifiable” myelodysplastic syndrome. Leukemia, 10, 20–6Google ScholarPubMed

Boultwood, J., Lewis, S., and Wainscoat, J. S. (1994). The 5q− syndrome. Blood, 84, 3253–60Google ScholarPubMed

Gregg, X. T., Reddy, V., and Prchal, J. T. (2002) Copper deficiency masquerading as myelodysplastic syndrome. Blood, 100, 1493–5CrossRefGoogle ScholarPubMed

Irving, J. A., Mattman, A., Lockitch, G., and Farrell, K. (2003). Element of caution: a case of reversible cytopenias associated with excessive zinc supplementation. C.M.A.J., 169, 129–31Google ScholarPubMed

Rosati, S., Anastasi, J., and Vardiman, J. (1996). Recurring diagnostic problems in the pathology of the myelodysplastic syndromes. Semin. Hematol., 33, 111–26Google ScholarPubMed

Westhoff, D. D., Samaha, R. J., and Barnes, A. Jr. (1975). Arsenic intoxication as a cause of megaloblastic anemia. Blood, 45, 241–6Google ScholarPubMed

Baurmann, H., Schwatz, T. F., Oertel, J.et al. (1992). Acute parvovirus infection mimicking myelodysplastic syndrome of the bone marrow. Ann. Hematol., 64, 43–5CrossRefGoogle ScholarPubMed

Schmitz, L. L., McClure, J. S., Litz, C. E.et al. (1994). Morphologic and quantitative changes in blood and marrow cells following growth factor therapy. Am. J. Clin. Pathol., 101, 67–75CrossRefGoogle ScholarPubMed

Katoutsi, V., Kohlmeyer, U., Maschek, H.et al. (1994). Comparison of bone marrow and hematologic findings in patients with human immunodeficiency virus infection and those with myelodysplastic syndromes and infectious disease. Am. J. Clin. Pathol., 101, 123CrossRefGoogle Scholar

Treacy, M., Lai, L., Costello, C., and Clark, A. (1987). Peripheral blood and bone marrow abnormalities in patients with HIV related disease. Br. J. Haematol., 65, 289–94CrossRefGoogle ScholarPubMed

Delacetaz, F., Schmidt, P. M., Piguet, D.et al. (1987). Histopathology of myelodysplastic syndromes. Am. J. Clin. Pathol., 87, 180–6CrossRefGoogle Scholar

Germing, U., Gattermann, N., Aivado, M.et al. (2000). Two types of acquired idiopathic sideroblastic anaemia (AISA): a time-tested distinction. Br. J. Haematol., 108, 724–8CrossRefGoogle ScholarPubMed

Greenberg, P., Cox, C., Beau, M. M.et al. (1997). International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 89, 2079–88Google ScholarPubMed

Bernstein, S. H., Brunetto, V. L., and Davey, F. R. (1996). Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndromes as defined by French–American–British criteria: a Cancer and Leukemia Group B study. J. Clin. Oncol., 14, 2486–94CrossRefGoogle ScholarPubMed

Estey, E., Pierce, S., Kantarjian, H.et al. (1993). Treatment of myelodysplastic syndromes with AML-type chemotherapy. Leuk. Lymphoma, 11 (suppl. 2), 59–63CrossRefGoogle ScholarPubMed

Estey, E., Thall, P., Beran, M.et al. (1997). Effects of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. Blood, 90, 2969–77Google Scholar

Vardiman, J. W., Harris, N. L., and Brunning, R. D. (2002). The World Health Organization (WHO) classification of myeloid neoplasms. Blood, 100, 2292–302CrossRefGoogle ScholarPubMed

Menke, D. M., Colon-Otero, G., Cockerill, K. J.et al. (1992). Refractory thrombocytopenia: a myelodysplastic syndrome that may mimic immune thrombocytopenic purpura. Am. J. Clin. Pathol., 98, 502–10CrossRefGoogle ScholarPubMed

Tricot, G., Criel, A., and Verwilghen, R. L. (1982). Thrombocytopenia as presenting symptom of preleukaemia in three patients. Scand. J. Haematol., 28, 243–50CrossRefGoogle Scholar

Steensma, D. P., DeWald, G. W., Hodnefield, J. M.et al. (2003). Clonal cytogenetic abnormalities in bone marrow specimens without clear morphologic evidence of dysplasia: a form fruste of myelodysplasia?Leuk. Res., 27, 235–42CrossRefGoogle ScholarPubMed

Olney, H. J. and Le Beau, M. M. (2002). Cytogenetics and molecular biology of myelodysplastic syndromes. In The Myelodysplastic Syndromes, Pathobiology and Clinical Management, ed. , J. M. Bennett. New York:Marcel Dekker, pp. 89–119Google Scholar

Rigolin, G. M., Bigoni, R., Milani, R.et al. (2001). Clinical importance of interphase cytogenetics detecting occult chromosome lesions in myelodysplastic syndromes with normal karyotype. Leukemia, 15, 1841–7CrossRefGoogle ScholarPubMed

Cermak, J., Michalova, K., Brezinova, J.et al. (2003). A prognostic impact of separation of refractory cytopenia with multilineage dysplasia and 5q− syndrome from refractory anemia in primary myelodysplastic syndrome. Leuk. Res., 27, 221–9CrossRefGoogle ScholarPubMed

Giagounidis, A. N. N., Germing, U., Haase, S.et al. (2004). Clinical, morphological, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia, 18, 113–19CrossRefGoogle ScholarPubMed

Lai, F., Godley, L. A., Joslin, J.et al. (2001). Transcript map and comparative analysis of the 1.5 Mb commonly deleted segment of human 5q31 in malignant myeloid diseases with a del (5q). Genomics, 71, 235–45CrossRefGoogle Scholar

Kurtin, P. J., Dewald, G. W., Shields, D. J., and Hanson, C. A. (1996). Hematologic disorders associated with deletions of chromosome 20q: a clinicopathologic study of 107 patients. Am. J. Clin. Pathol., 106, 680–8CrossRefGoogle ScholarPubMed

Lai, J. L., Preudhomme, C., Zandecki, M.et al. (1995). Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoiesis and a high incidence of P53 mutations. Leukemia, 9, 370–81Google Scholar

Sankar, M., Tanaka, K., Kumaravel, T. S.et al. (1998). Identification of a commonly deleted region at 17p13.3 in leukemia and lymphoma associated with 17p abnormality. Leukemia, 12, 510–16CrossRefGoogle ScholarPubMed

Ellis, M., Ravid, M., and Lishner, M. (1993). A comparative analysis of alkylating agent and epipodophyllotoxin-related leukemias. Leuk. Lymphoma, 11, 9–13CrossRefGoogle ScholarPubMed

Godley, L. A. and Larson, R. A. (2002). The syndrome of therapy related myelodysplasia and myeloid leukemia. In The Myelodysplastic Syndromes, Pathobiology and Clinical Management, ed. , J. M. Bennett. New York: Marcel Dekker, pp. 139–76Google Scholar

Latagliata, R., Petti, M. C., Fenu, S.et al. (2002). Therapy-related myelodysplastic syndrome–acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem. Blood, 99, 822–4CrossRefGoogle ScholarPubMed

Beau, , , M. M., Albain, K. S., Larson, R. A.et al. (1986). Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. J. Clin. Oncol., 4, 325–45CrossRefGoogle ScholarPubMed

Merlat, A., Lai, J. L., Sterkers, Y.et al. (1999). Therapy-related myelodysplastic syndrome and acute myeloid leukemia with 17p deletion. A report on 25 cases. Leukemia, 13, 250–7CrossRefGoogle ScholarPubMed

Michels, S. D., McKenna, R. W., Arthur, D. C., and Brunning, R. D. (1985). Therapy-related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphologic study of 65 cases. Blood, 65, 1364–72Google ScholarPubMed

Pedersen-Bjergaard, J., Andersen, M. K., Christiansen, D. H., and Nerlov, C. (2002). Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. Blood, 99, 1909–12CrossRefGoogle ScholarPubMed

Pedersen-Bjergaard, J., Phillip, P., Larsen, S. O.et al. (1993). Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant disease in the Copenhagen series. Leukemia, 7, 1975–86Google Scholar

Pedersen-Bjergaard, J. (2005). Insights into leukemogenesis from therapy-related leukemia. N. Engl. J. Med., 352, 1591–4CrossRefGoogle ScholarPubMed

Quesnel, B., Kantarjian, H., Pedersen-Bjergaard, J.et al. (1993). Therapy-related acute myeloid leukemia with t(8;21), Inv(16) and t(8;16): a report on 25 cases and review of the literature. J. Clin. Oncol., 11, 2370–9CrossRefGoogle Scholar

Pui, C. H., Relling, M. V., Rivera, G. K.et al. (1995). Epipodophyllotoxin-related acute myeloid leukemia; a study of 35 cases. Leukemia, 9, 1990–6Google ScholarPubMed

Rowley, J. D. and Olney, H. J. (2002). International workshop on the relationship of prior therapy to balanced chromosome aberrations in therapy-related leukemia and myelodysplastic syndromes and acute leukemia: overview report. Genes Chromosomes Cancer, 33, 331–45CrossRefGoogle ScholarPubMed

Secker-Walker, L. M., Moorman, A. V., Bain, B. J., and Mehta, A. B. (1998). Secondary acute leukemia and myelodysplastic syndrome with 11q23 abnormalities: EU concerted action 11q23 workshop. Leukemia, 12, 840–4CrossRefGoogle ScholarPubMed

Lobe, I., Rigal-Huguet, F., Vekhoff, A.et al. (2003). Myelodysplastic syndrome after acute promyelocytic leukemia: the European APL group experience. Leukemia, 17, 1600–4CrossRefGoogle ScholarPubMed

Rios, A., Canizo, M. C., Sanz, A.et al. (1990). Bone marrow biopsy in myelodysplastic syndromes: morphologic characteristics and contribution to the study of prognostic factors. Br. J. Haematol., 75, 26–33CrossRefGoogle Scholar

Tomonga, M. and Nagai, K. (2002). Hypocellular myelodysplastic syndromes and acute myeloid leukemia: relationship to aplastic anemia. In The Myelodysplastic Syndromes, Pathobiology and Clinical Management, ed. , J. M. Bennett. New York: Marcel Dekker, pp. 121–38Google Scholar

Tricot, G., DeWolf-Peeters, C., Vlietinck, R., and Verwilghen, R. L. (1984). Bone marrow histology in myelodysplastic syndromes II. Prognostic value of abnormal localization of immature precursors in MDS. Br. J. Haematol., 58, 217–25CrossRefGoogle ScholarPubMed

Lambertenghi-Deliliers, G., Annaloro, C., Oriani, A., and Soligo, D. (1992). Myelodysplastic syndrome associated with bone marrow fibrosis. Leuk. Lymphoma, 8, 51–5CrossRefGoogle ScholarPubMed

Maschek, H., Georgii, A., Kaloutsi, V.et al. (1992). Myelofibrosis in primary myelodysplastic syndromes: a retrospective analysis of 352 patients. Eur. J. Haematol., 48, 208–14CrossRefGoogle Scholar

Steensma, D. P., Hanson, C. A., Letendre, L., and Tefferi, A. (2001). Myelodysplasia with fibrosis: a distinct entity?Leuk. Res., 25, 829–38CrossRefGoogle ScholarPubMed

Sultan, C., Sigaux, F., Imbert, M., and Reyes, F. (1981). Acute myelodysplasia with myelofibrosis: a report of eight cases. Br. J. Haematol., 49, 11–16CrossRefGoogle ScholarPubMed

Tuzuner, N., Cox, C., Rowe, J. M.et al. (1995). Hypocellular myelodysplastic syndromes (MDS): new proposals. Br. J. Haematol., 91, 612–17CrossRefGoogle ScholarPubMed

Yoshida, Y., Oguma, S., Uchino, H., and Maekawa, T. (1988). Refractory myelodysplastic anaemias with hypocellular bone marrow. J. Clin. Pathol., 41, 763CrossRefGoogle ScholarPubMed

Maschek, H., Kaloutsi, V., Rodriguez-Kaiser, M.et al. (1993). Hypoplastic myelodysplastic syndrome: incidence, morphology, cytogenetics and prognosis. Ann. Hematol., 66, 117–22CrossRefGoogle ScholarPubMed

Orazi, A., Albiter, M., Heerema, N. A.et al. (1997). Hypoplastic myelodysplastic syndrome can be distinguished from acquired aplastic anemia by CD34 and PCNA immunostaining of bone marrow biopsy specimens. Am. J. Clin. Pathol., 107, 268–74CrossRefGoogle ScholarPubMed

Barrett, J., Saunthararajah, Y., and Molldrem, J. (2000). Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology?Semin. Hematol., 37, 15–29CrossRefGoogle ScholarPubMed

Group Français de Cytogénetique Hématologique (1991). Chronic myelomonocytic leukemia: single entity or heterogeneous disorder? A prospective multicenter study of 100 patients. Cancer Genet. Cytogenet, 55, 57–65CrossRef

Krsnik, I., Srivastava, P. C., and Galton, D. A. G. (1992). Chronic myelomonocytic leukaemia and atypical chronic myeloid leukaemia. In Myelodysplastic Syndromes, ed. , F. Schmalzl and , G. J. Multi. New York: Springer-Verlag, pp. 131–9Google Scholar

Nossinger, T., Reisner, R., Gruner, H.et al. (2000). Dysplastic versus proliferative CMML – a retrospective analysis of 91 patient from a single institution. Leuk. Res., 25, 741–7CrossRefGoogle Scholar

Shepherd, P. C., Ganesan, T. S., and Galton, D. A. (1987). Haematological classification of the chronic myeloid leukaemias. Baillière's Clin. Haematol., 1, 887–906CrossRefGoogle ScholarPubMed

Vardiman, J. W. (2001). Myelodysplastic/myeloproliferative disease: introduction. In World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, ed. , E. S. Jaffe, , N. L. Harris, , H. Stein, and , J. W. Vardiman. Lyon: IARC Press, pp. 47–48Google Scholar

Germing, U., Gattermann, N., Minning, H.et al. (1998). Problems in the classification of CMML – dysplastic versus proliferative type. Leuk. Res., 22, 871–8CrossRefGoogle ScholarPubMed

Steensma, D. P., Tefferi, A., and Li, C. Y. (2003). Splenic histopathological variants in chronic myelomonocytic leukemia: reinforcement of the heterogeneity of the syndrome. Leuk. Res., 27, 775–82CrossRefGoogle Scholar

Vardiman, J. W. (2003). Myelodysplastic syndromes, chronic myeloproliferative diseases, and myelodysplastic/myeloproliferative diseases. Semin. Diag. Pathol., 20, 154–79CrossRefGoogle ScholarPubMed

Bennett, J. M., Catovsky, D., Daniel, M. T.et al. (1994). The chronic myeloid leukemias: guidelines for distinguishing the chronic granulocytic, atypical chronic myeloid and chronic myelomonocytic leukaemias. Br. J. Haematol., 87, 746–54CrossRefGoogle Scholar

Greenberg, P., Anderson, J., Witte, , , T.et al. (2000). Problematic WHO reclassification of myelodysplastic syndromes. J. Clin. Oncol., 18, 3447–9Google ScholarPubMed

Chen, T.-C., Chou, J.-M., Ketterling, R. P.et al. (2003). Histologic and immunohistochemical study of bone marrow monocytic nodules in 21 cases with myelodysplasia. Am. J. Clin. Pathol., 120, 874–81CrossRefGoogle ScholarPubMed

Side, L. E., Emanuel, P. D., Taylor, B.et al. (1998). Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1. Blood, 92, 267–72Google ScholarPubMed

Niemeyer, C. M., Fenu, S., Hasle, H.et al. (1998). Differentiating juvenile myelomonocytic leukemia from infectious disease. Blood, 91, 365–7Google Scholar

Hasle, H. and Niemeyer, C. (2002). Myelodysplastic syndrome and juvenile myelomonocytic leukemia in children. In The Myelodysplastic Syndromes, Pathobiology and Clinical Management, ed. , J. M. Bennett. New York: Marcel Dekker, pp. 299–344Google Scholar

Hasle, H., Niemeyer, C. M., Chessells, J. M.et al. (2003). A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia, 17, 277–82CrossRefGoogle ScholarPubMed

Gurbuxani, S., Vyas, P., and Crispino, J. D. (2004). Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome. Blood, 103, 399–406CrossRefGoogle ScholarPubMed

Hasle, H., Clemmensen, I. H., and Mikkelsen, M. (2000). Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet, 355, 165–9CrossRefGoogle ScholarPubMed

Lange, B. J., Kobrinsky, N., Barnard, D. R.et al. (1998). Distinct demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Study Group Studies 2861 and 2891. Blood, 91, 608–15Google Scholar

Lange, B. (2000). The management of neoplastic disorders of haematopoiesis in children with Down's syndrome. Br. J. Haematol., 110, 512–24CrossRefGoogle ScholarPubMed

Ma, S. K., Wan, T. S. K., Chan, G. C. F.et al. (2001). Relationship between transient abnormal myelopoiesis and acute megakaryoblastic leukaemia in Down's syndrome. Br. J. Haematol., 112, 824–5CrossRefGoogle ScholarPubMed

Mundschau, G., Gurbuxani, S., Gamis, A. S.et al. (2003). Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis. Blood, 101, 4298–300CrossRefGoogle ScholarPubMed

Zipursky, A. (2003). Transient leukaemia – a benign form of leukaemia in newborn infants. Br. J. Haematol., 120, 930–8CrossRefGoogle ScholarPubMed

Hitzler, J. K., Cheung, J., Li, Y.et al. (2003). GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome. Blood, 101, 4301–4CrossRefGoogle ScholarPubMed

Rainis, L., Bercovich, D., Strehl, S.et al. (2003). Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. Blood, 102, 981–6CrossRefGoogle ScholarPubMed

Wechsler, J., Greene, M., McDevitt, M.et al. (2002). Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat. Genet., 32, 148–52CrossRefGoogle ScholarPubMed

Heaney, M. L. and Golde, D. W. (1999). Myelodysplasia. N. Engl. J. Med., 340, 1649–60CrossRefGoogle ScholarPubMed

Steensma, D. P. and Tefferi, A. (2003). The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. Leuk. Res., 27, 95–120CrossRefGoogle ScholarPubMed

Brunning, R. D. (2003). MDS – new classification, new problem?Leuk. Res., 27, 567–9CrossRefGoogle Scholar

Cobo, F., Quinto, L. L., Rozman, M.et al. (2003). Analysis of 178 myelodysplastic syndrome patients: validation of the World Health Organization classification and the International Prognostic Scoring System. Leuk. Res., 27, S18–19Google Scholar

Germing, U., Gattermann, N., Strupp, C.et al. (2000). Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk. Res., 24, 983–92CrossRefGoogle ScholarPubMed

Howe, R., Porwit-MacDonald, A., Wanat, R.et al. (2004). The WHO classification of MDS does make a difference. Blood, 103, 3265–70CrossRefGoogle Scholar

Lee, J. H., Lee, J. H., Shin, Y. R.et al. (2003). Application of different prognostic scoring systems and comparison of the FAB and WHO classifications in Korean patients with myelodysplastic syndrome. Leukemia, 17, 305–13CrossRefGoogle ScholarPubMed

Nosslinger, T., Reisner, R., Koller, E.et al. (2002). Myelodysplastic syndromes from French–American–British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution. Blood, 98, 2935–41CrossRefGoogle Scholar

Strupp, C., Gattermann, N., Giagounidis, A.et al. (2003). Refractory anemia with excess of blasts in transformation: analysis of reclassification according to the WHO proposals. Leuk. Res., 27, 397–404CrossRefGoogle ScholarPubMed

Head, D. R. (1996). Revised classification of acute myeloid leukemia. Leukemia, 10, 1826–31Google ScholarPubMed

Willman, C. L. (1998). Molecular genetic features of myelodysplastic syndromes. Leukemia, 12, S2–6Google ScholarPubMed

Wattel, E., DeBotton, S., Luc Lai, J.et al. (1997). Long-term follow-up of de novo myelodysplastic syndromes treated with intensive chemotherapy: incidence of long-term survivors and outcome of partial responders. Br. J. Haematol., 98, 983–91CrossRefGoogle ScholarPubMed

DeWitte, T., Sucio, S., Peetermans, M.et al. (1995). Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia following MDS of more than 8 months duration. A pilot study by the Leukemia Committee of the EORTC. Leukemia, 9, 1805.Google Scholar